ProfileGDS5678 / 1416422_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 93% 93% 91% 92% 91% 88% 91% 90% 92% 91% 92% 91% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.4090391
GSM967853U87-EV human glioblastoma xenograft - Control 27.8940493
GSM967854U87-EV human glioblastoma xenograft - Control 38.0254193
GSM967855U87-EV human glioblastoma xenograft - Control 47.6987691
GSM967856U87-EV human glioblastoma xenograft - Control 57.6144992
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.2614191
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.7194388
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.2819891
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.1532990
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.5599292
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.4711991
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.5821792
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.4535291
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.4651891